GLP-1R agonists may exert antidepressant effects by modulating inflammatory processes in the brain Chronic inflammatory processes in the brain associated with excessive activation of microglia and increased production of pro-inflammatory cytokines are one of the key factors leading to the development of depressive symptoms, as patients suffering from this mental illness are very often characterized by elevated levels of tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), interleukin-1 beta (IL-1), C-reactive protein (CRP), and interferon-gamma (IFN-) in the cerebrospinal fluid and the blood [59,60,61]
Vitamin E) bind to and immobilise ROS
The appropriate dosage of TB-500 can vary significantly depending on the individuals condition, therapeutic goals, and the treatment plan prescribed by a licensed medical professional
The FDA initially approved subcutaneous (SC) use Exenatide in 2005 and an oral version of semaglutide in 2019.2,3 Initially, GLP-1s were used exclusively for individuals with type 2 diabetes (T2DM) as a means to better control their blood sugar when paired with diet and exercise.2 Now their use is growing exponentially due to their success in helping patients achieve significant weight loss
(Morand et al., 2013), Isaguirre et al
)
